BenevolentAI Investor Presentation Deck
New strategic plan to position BenevolentAl for a new era
ORGANISATIONAL
CHANGES
REDUCING
COST BASE
FOCUSING ON
HIGH-VALUE ASSETS
Prioritising the most
advanced assets,
progressing them to
their next value inflection
points
Expected net cost
savings of £45m,
extending the cash
runway to at least July
2025 (before any new
revenue)
Other drug
programmes will be
paused, with a review
underway to optimise
value for these assets
• Retaining key
capabilities in drug
discovery and target
identification
COMMERCIALISING
AI TECH PLATFORM
Commercialising our
innovative technology
platform through new
revenue-generating
products, collaborations
and partnerships
Planned launch of a new
suite of products that
enable biopharma
companies to advance
new discoveries by
harnessing the power of
Al
●
Aligning the
organisational structure
to the new strategic
direction, improving
capital efficiency and
operational effectiveness
Streamlining operations
across two business
units: Bio and Tech,
supported by Shared
Business Ops
Building a commercial
function to drive
revenue growth
●
Cost savings driven by
headcount reductions of
up to approximately 180
employees, reduced lab
and office footprint, and
the pause of selected
drug programmes
The strategic plan maximises the potential of our portfolio and expands our differentiated
technology platform to meet a moment of opportunity for Al in biopharma
Benevolent 3View entire presentation